Athira Pharma, Inc. is advancing a novel, potentially transformative approach for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Unlike other products approved and in ...

BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health ...

Athira Pharma, Inc. ( ($ATHA) ) has released its Q4 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its ...

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.

What is the Fund Sentiment? There are 105 funds or institutions reporting positions in Athira Pharma. This is a decrease of 22 owner(s) or 17.32% in the last quarter. Average portfolio weight of ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Athira Pharma, Inc, a late clinical-stage biopharmaceutical company ...

Four Malayalis, including captain Athira Sunil, are representing England's women's kabaddi team in the Kabaddi World Cup 2025 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The England kabaddi teams, featuring several Malayalis, will showcase their skills at the World Cup 2025. Both the women's ...